Canadian Technology Stocks and Startups
Tekmira (TSX:TKM, Nasdaq:TKMR) has always had a compelling story -the company is a pioneer in a exciting new area of medicine with best-in-class technology -but until very recently it lacked a broad investor audience. In late 2013, however, the company made some strategic decisions that helped grow its investor appeal greatly and turned the stock [...]
In the U.S., biotech stocks partied like it was 1999 last year, delivering a spike that was second only to that year’s 102% gain. But Steve Silver, a biotech analyst at S&P Capital IQ, says the long overlooked sector isn’t overvalued. “The extent to which these companies have gone up this year would suggest that [...]
Revive Therapeutics (TSXV:RVV) today announced results from a Phase 2a proof-of-concept study it called “encouraging”. The study aimed to discover if the company’s REV-001 treatment for the prevention of opioid-induced respiratory depression was safe and effective. Preliminary data showed that REV-001 was well tolerated, did not affect analgesia and showed encouraging clinical activity in resting [...]
Cantor Fitzgerald analyst Justin Kew attended the annual Pharmacy Benefit Management Institute’s Drug Benefit Conference in Las Vegas earlier this week, and came away feeling his bullish take on Catamaran Corp. (TSX:CCT) was confirmed. Kew says the growth of specialty drugs was a major theme of the conference. Specialty drugs, which are prescribed for chronic [...]
Robust M&A activity drove overall sector valuations in fiscal 2013, and we believe expectations of same will continue to support near term healthcare valuations at or above current levels in fiscal 2014. In particular, we expect specialty pharma and pharma out-sourcing valuations to outperform as they did last year, driven by strong EBITDA margins that [...]
Canada’s Life Sciences sector weathered a tough road in the wake of 2008, but bounced back in 2013 to join the innovation sectors in leading the Canadian markets. Here are the nominees for the 2013 Cantech Letter Canadian Life Sciences Stock of the Year. This year, for the first time ever, the Cantech Letter Awards [...]
When we first caught up with Verisante (TSXV:VRS) CEO Thomas Braun, the company was adding engineering staff to further the develompment of Aura, its skin cancer detection device. Today, Verisante is embarking on a controlled rollout of the device, after gathering valuable data from a limited release to a half-dozens clinics. 2014 will be a [...]
Shares of junior Titan Medical (TSXV:TMD) are way up today, and the company says it isn’t sure why. At the request of IIROC, Titan issued the familiar release that it wasn’t aware of any material change that would cause its shares to spike. But management pointed to its release of November 11th that detailed the [...]
Canaccord analyst Neil Maruoka says recently completed acquisitions will drive Valeant Pharmaceuticals (TSX:VRX) soon to be released third quarter numbers. On Thursday, before the market open, Valeant will reports its Q3 numbers. The company is following on second quarter in which it posted total revenue $1.1 billion, which was an increase of 41% over the [...]
Prometic Life Sciences (TSX:PLI) is fast becoming one of the most talked about biotech success stories on the TSX this year. Shares of Prometic have caught fire in the latter half of 2013, rising from barely thirty cents in July to recent highs over $.90. The reason? Investors are increasingly optimistic that PBI-4050, Prometic’s new [...]
